source
- Sanofi, Regeneron expand partnership with $1 billion deal to develop next-generation Dupixent-like antibodiesSanofi and Regeneron announced they have broadened their long‑standing alliance, adding a $1 billion upfront payment to fund joint work on new immune‑modulating drugs. The revised agreement calls…
- Pfizer's experimental eczema drug tilrekimig shows strong skin clearance in Phase 2 trialPfizer reported that its three‑pronged antibody, tilrekimig, met the primary endpoint of its Phase 2 study in patients with moderate to severe atopic dermatitis. After 16 weeks, a significantly hig…BioPharma Dive · 20d agoPositive readoutPositive